We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration (nAMD), the most common cause of blindness in patients over 60 worldwide.